Cellular immunotherapy currently achieves significant efficacy in chronic myeloid leukemia, acute myeloid leukemia, non-Hodgkin’s lymphoma, and multiple myeloma. The first CAR-T treatment (KymriahTM) was approved by the FDA on August 31, 2017 for the treatment of two or more relapses under the age of 25 in patients with B-cell precursor… Continue Reading Prospect of cellular immunotherapy for liver cancer

CAR-T therapy has attracted wide attention due to its bright prospects in the treatment of cancers such as leukemia and lymphoma. This new type of therapy, which has just entered the market, usually requires the injection of hundreds of millions of genetically engineered T cells into patients. However, in a… Continue Reading Only one cell is used to cure a cancer patient!

This aspirin tablet-sized implant made from biodegradable materials will likely activate the patient’s anti-tumor immune response, thereby producing an anti-tumor effect. Implantable tumor vaccine Immunotherapy, which can activate the patient’s own immune system and kill tumor cells, is probably the hottest area of ​​research and development of new drugs today.… Continue Reading Frontiers: Can tumor immune implants become a new breakthrough in cancer vaccines?

I Mysterious disappearing tumor In the oncology department for a long time, there is always a chance to meet miracles. About ten years ago, Archie Tse also worked at the Sloan-Kettering Cancer Center. At that time, he took over a patient with advanced pancreatic cancer. The prognosis of most patients… Continue Reading STING Hunter: Can a new generation of therapy sweep the field of tumor immunity?

Immune escape of tumor In the last article, I talked about the process of Munn finding IDO immunosuppression. However, when Munn is cultured for macrophage /T cells, tryptophan may not be a simple nutrient, but more likely to be a signal molecule. For many people, this view is really unacceptable.… Continue Reading The story behind the IDO inhibitor (next)